Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 10 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue declined because there were no major new products, expansion of sales offices and BM locations was sluggish, and some enhanced products and regular products performed weakly. The cost of sales ratio increased because of higher material and raw material prices, while selling, general and administrative expenses also increased because of higher prices overall.
| Item | Details |
|---|---|
| Net Sales | ¥2,850 million → ¥2,641 million（-7.3%） |
| Operating profit | ¥380 million → ¥195 million（-48.7%） |
| Ordinary income | ¥380 million → ¥192 million（-49.5%） |
| Profit attributable to owners of the parent | ¥315 million → ¥164 million（-47.9%） |
| Net income per share | 47.52 yen → 22.45 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 10 February 2026 |
| Previous-period results | Previous fiscal year actual results: revenue of ¥2,929 million, operating income of ¥422 million, ordinary income of ¥420 million, net income of ¥43 million, and earnings per share of ¥2.44 (full year of the fiscal year ended March 2025) |
| Reason for the revision | Revenue declined because there were no major new products, expansion of sales offices and BM locations was sluggish, and some enhanced products and regular products performed weakly. The cost of sales ratio increased because of higher material and raw material prices, while selling, general and administrative expenses also increased because of higher prices overall. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined because there were no major new products, expansion of sales offices and BM locations was sluggish, and the White Power Serum and regular products performed weakly. In addition, the cost of sales ratio and selling, general and administrative expenses increased because of higher material and raw material prices and overall inflation.